The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.-F.
Right arrow Articles by Lin, Y.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-F.
Right arrow Articles by Lin, Y.-S.
The Journal of Immunology, 2002, 169: 657-664.
Copyright © 2002 by The American Association of Immunologists

Endothelial Cell Apoptosis Induced by Antibodies Against Dengue Virus Nonstructural Protein 1 Via Production of Nitric Oxide1

Chiou-Feng Lin*, Huan-Yao Lei*, Ai-Li Shiau*, Hsiao-Sheng Liu*, Trai-Ming Yeh{dagger}, Shun-Hua Chen*, Ching-Chuan Liu{ddagger}, Shu-Chen Chiu* and Yee-Shin Lin2,*

Departments of * Microbiology and Immunology, {dagger} Medical Technology, and {ddagger} Pediatrics, National Cheng Kung University Medical College, Tainan, Taiwan, Republic of China


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The onset of vascular leakage and hemorrhagic diathesis is one of the life-threatening complications occurring in dengue patients, yet the pathogenic mechanisms are not well understood. In this study, we demonstrated that Abs against dengue virus nonstructural protein 1 (NS1) generated in mice cross-reacted with human endothelial cells and mouse vessel endothelium. After binding, mouse anti-NS1 Abs induced endothelial cell apoptosis in a caspase-dependent manner. Inducible NO synthase expression could be observed; it showed a time- and dose-dependent correlation with NO production. Endothelial cell apoptosis, characterized by exposure of phosphatidylserine on the cell surface and nuclear DNA fragmentation, was blocked by treatment with the NO synthase inhibitor N{omega}-nitro-L-arginine methyl ester. Further studies demonstrated that the expression of Bcl-2 and Bcl-xL decreased in both mRNA and protein levels, whereas p53 and Bax increased after anti-NS1 treatment. Cytochrome c release was also observed. All of these effects could be inhibited by N{omega}-nitro-L-arginine methyl ester. Taken together, anti-NS1 Abs act as autoantibodies that cross-react with noninfected endothelial cells and trigger the intracellular signaling leading to the production of NO and to apoptosis. Endothelial cell damage may cause vascular leakage that contributes to the pathogenesis of dengue disease.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Dengue virus (DV),3 a member of the genus Flavivirus within the family Flaviviridae, causes a wide range of diseases from mild dengue fever (DF) to severe dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) (1, 2, 3). The typical biphasic fever, headache, body pain, and rash characterize clinical manifestations of DF. In some cases, however, patients develop the life-threatening syndrome DHF/DSS, which is characterized by abnormalities of hemostasis and vascular permeability (3). To date, there are no effective strategies to prevent the progression of DHF/DSS, because its pathogenic mechanisms are not fully understood (4, 5). Ab-dependent enhancement of infection has been suggested as an explanation of the high risk for hemorrhage and shock syndrome in the secondary heterologous DV infection (6, 7, 8, 9, 10). Virus variation may also be responsible for the severity of dengue disease (11, 12, 13, 14). In addition to a direct effect of DV, abnormal immune responses to DV infection, such as the production of cytokines or chemokines and the activation of complement or immune cells, may also underlie the pathogenesis of disease (15, 16, 17, 18, 19, 20, 21, 22). Accumulated evidence has shown that host cell apoptosis induced by DV infection may also be involved (22, 23, 24, 25, 26, 27). It is likely that several mechanisms are involved in the pathogenesis of DV infection, although their relative importance remains undefined.

Hemorrhagic syndrome, a feature of DHF/DSS, is a hematologic abnormality resulting from multiple factors, including thrombocytopenia, coagulopathy, and vasculopathy (28, 29). The pathogenesis of endothelial dysfunction related to vascular leakage syndrome is not well understood. Ab-enhanced infection of DV in peripheral blood monocytes could modulate endothelial cell function by an indirect route (30). Complement activation and chemokine production induced by DV infection are also suggested to be involved in the induction of endothelial cell damage (22, 31). Several in vitro studies have reported that endothelial cells were the targets of DV (21, 22, 31) and that cell apoptosis was directly caused by DV (22). Thus, endothelial cell apoptosis may be related to the disruption of the endothelial barrier and then lead to the transient leakage syndrome in dengue vasculopathy.

Mouse anti-dengue virus nonstructural protein 1 (NS1) Abs had been shown to cross-react with human endothelial cells (32). In the present study, we demonstrated that endothelial cells underwent apoptosis after being bound by anti-NS1 Abs generated in mice. The signaling pathways were investigated and showed the expression of inducible NO synthase (iNOS) and the production of NO after induction by anti-NS1. Addition of the NO synthase (NOS) inhibitor protected cells from anti-NS1-induced apoptosis. The possible relations of NO production with the changes in Bcl-2, Bcl-xL, Bax, and p53 expression and cytochrome c release were also demonstrated.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mice

BALB/cByJ breeder mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained on standard laboratory food and water ad libitum in our medical college laboratory animal center. Their 8-wk-old progeny were used for the experiments in the present study.

Abs and reagents

Rabbit Abs specific for the active form of human caspase-3 or for both pro (32 kDa) and active caspase-3 (17–22 kDa) were purchased from BD PharMingen (San Diego, CA). Rabbit anti-human Abs to NOS II (iNOS) or NOS III (endothelial NO synthase; eNOS) were from Chemicon (Temecula, CA). Rat anti-mouse CD31 Ab, mouse anti-human Bcl-2 mAb, rabbit anti-human Bax Ab, and mouse anti-human p53 mAb were from Serotec (Oxford, U.K.); mouse anti-human Bcl-xL mAb and mouse anti-cytochrome c mAb were from BD PharMingen; and mouse mAb to {beta}-actin was from Sigma-Aldrich (St. Louis, MO). FITC- or HRP-conjugated goat anti-mouse or anti-rabbit IgG were obtained from ICN Pharmaceuticals (Aurora, OH). The caspase inhibitor, benzyloxycarbonylvalylalanylaspartic acid fluoromethyl ketone (zVAD-fmk), and caspase-3 inhibitor, aspartylglutamylvalylaspartic acid fluoromethyl ketone (DEVD-fmk), were purchased from Clontech Laboratories (Palo Alto, CA). The NOS inhibitor N{omega}-nitro-L-arginine methyl ester (L-NAME) was obtained from Sigma-Aldrich.

Preparation of recombinant NS1

The full-length DV-2 (New Guinea C strain) NS1 cDNA was cloned to pRSET B expression vector (Invitrogen, Carlsbad, CA) to establish a pRSET-DVNS1 plasmid. After the sequences at the 5' and 3' junctions were confirmed, this plasmid was then introduced into Escherichia coli BL21(DE3)pLysS strain (Invitrogen). The recombinant NS1 proteins were induced by a 2 mM final concentration of isopropyl {beta}-D-thiogalactoside and purified with TALON metal affinity resin (Clontech Laboratories). A single band was detected by SDS-PAGE, and the protein sequence was confirmed by an Applied Biosystems 477A autosequencer (Foster City, CA).

The plasmid construct expressing full-length Japanese encephalitis virus (JEV) NS1, pET-32a(+)-JNS1, was obtained from Dr. S. L. Hsieh (National Yang-Ming University, Taipei, Taiwan) and Dr. Y. L. Lin (Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan). This plasmid was derived from pcDNA3-JNS1 which was constructed from JEV strain NT109 as previously described (33, 34). The plasmid was transformed into the E. coli BL21(DE3)pLysS strain. The recombinant protein expression and purification followed the procedures described above for DV2 NS1 preparation.

Generation of anti-NS1 Abs

BALB/c mice were immunized i.p. with 25 µg of purified recombinant DV or JEV NS1 proteins emulsified in CFA (Life Technologies, Gaithersburg, MD) and then four times in IFA. Sera were obtained 3 or 4 days after the last immunization. The IgG fractions from hyperimmunized mouse sera were purified with protein G-Sepharose affinity chromatography column (Amersham Pharmacia, Uppsala, Sweden) and recovered with HCl-glycine. The reactivity of purified IgG against NS1 was confirmed by SDS-PAGE and Western blot. The control IgG was eluted from protein G column loaded with normal mouse sera.

Cell culture

Human microvascular endothelial cell line-1 (HMEC-1) was obtained from the Centers for Disease Control and Prevention (Atlanta, GA) (35), and passed in culture plates containing endothelial cell growth medium (Clonetics, Walkersville, MD) composed of 2% FBS, 1 µg/ml hydrocortisone, 10 ng/ml epidermal growth factor, and antibiotics. Cells were detached using 1000 U/ml trypsin and 0.5 mM EDTA. Only those cultures from three to five passages with a viability of >95% by eosin Y staining were used for experiments.

Immunohistochemistry and flow cytometry for detection of endothelial cell binding activity

HMEC-1 cells were seeded either in monolayers on sterile glass slides coated with 1% gelatin for confocal microscopy or in suspensions at 5 x 105 cells for flow cytometric analysis. For preparation of a single-cell suspension, cells were detached from plates with 1000 U/ml trypsin and 0.5 mM EDTA. Cells were washed briefly in PBS, fixed with 1% paraformaldehyde in PBS at room temperature for 10 min, and washed again with PBS. Mouse anti-NS1 or control IgG were then incubated with cells at 4°C for 1 h. The glass slides for confocal microscopy detection were incubated in a humidified chamber. After three washings with PBS, cells were incubated with 1 µl of 1 mg/ml FITC-conjugated goat anti-mouse IgG at 4°C for 1 h and washed again with PBS. The binding activity of mouse anti-NS1 or control IgG to endothelial cells was observed with a confocal laser microscope (Leica TCS SPII, Nussloch, Germany) or analyzed by flow cytometry (FACScan; BD Biosciences, San Jose, CA) with excitation set at 488 nm. For confocal microscopy, 20-µm-thick serial sections of HMEC-1 cells were analyzed. Optical sections were obtained in 0.6-µm steps along the z-axis.

Binding activity of anti-NS1 with mouse vessel endothelium ex vivo

Mouse vessels, obtained from the small veins of BALB/c mice, were perfused with anti-CD31, anti-DV2 NS1, anti-JEV NS1, or control IgG and incubated at 4°C for 1 h. After they were washed three times with PBS, the vessels were perfused with OCT compound, and tissue blocks were prepared. The vessels were sliced into 3-µm-thick sections and fixed with 1% paraformaldehyde in PBS at room temperature for 10 min. After being washed with PBS, vessel sections were incubated with 0.3% H2O2 in PBS for 5 min to quench endogenous peroxidase activity and then washed again with PBS. Next, 1 µl of 1 mg/ml HRP-conjugated goat anti-mouse IgG was added and incubated at 4°C for 1 h. The binding ability was observable by following the manufacturer’s instructions for the AEC substrate kit (Zymed Laboratories, San Francisco, CA) and then using light microscopy.

TUNEL assay

HMEC-1 cells were cultured in plates and incubated with mouse anti-NS1 or control IgG in the culture medium for various time intervals. Cells were detached from plates with 1000 U/ml trypsin and 0.5 mM EDTA. After being washed, 1 x 106 cells were fixed with 1% paraformaldehyde in PBS for 10 min at room temperature and permeabilized with 70% ethanol at -20°C. The percentages of apoptotic cells were assessed by TUNEL reaction using the ApoAlert DNA fragmentation assay kit (Clontech Laboratories) according to the manufacturer’s instructions and then analyzed by flow cytometry.

DNA ladder analysis

HMEC-1 cells were cultured in plates and incubated with mouse anti-NS1 or control IgG. After 24 h, 5 x 107 cells were harvested from the culture plates by adding lysis buffer (5 mM Tris-HCl (pH 8.0), 20 mM EDTA, and 0.5% Triton X-100) at 4°C for 15 min. After centrifugation at 10,000 rpm for 10 min, the supernatant containing fragmented DNA was incubated with 50 µg/ml RNase (Sigma-Aldrich) at 37°C for 2 h, followed by the addition of a final concentration of 100 µg/ml proteinase K (Sigma-Aldrich), after which the mixture was incubated at 50°C overnight. After phenol-chloroform extraction, DNA was precipitated in 70% isopropanol and 20 µg/ml glycogen for 3 h at -70°C. The resulting pellet was resolved in TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA), and the DNA sample was analyzed by 2% agarose gel electrophoresis in buffer containing 90 mM Tris-acetate (pH 8.0) and 4 mM EDTA. Gel was stained with ethidium bromide at 1 µg/ml and viewed with UV light.

Immunohistochemical staining for detection of caspase-3 and iNOS

A monolayer of HMEC-1 cells was cultured on sterile glass slides followed by treatment with mouse anti-NS1 or control IgG for various time intervals. Cells were fixed with 1% paraformaldehyde in PBS at room temperature for 10 min and permeabilized with 70% ethanol. After being washed with PBS, cells were incubated with 0.3% H2O2 in PBS for 5 min to quench endogenous peroxidase activity and then washed again with PBS. One microliter of 0.1 mg/ml rabbit Abs, specific for active-form caspase-3 or for iNOS, was added to cells and incubated for 1 h at 4°C. After being washed three times with PBS, cells were incubated with 1 µl of 1 mg/ml HRP-conjugated goat anti-rabbit IgG for 1 h at 4°C. After being washed with PBS, cells were developed using the AEC substrate kit and viewed with light microscopy.

Western blot analysis

HMEC-1 cells were harvested from cultures after treatment with mouse anti-NS1 or control IgG for various time intervals. Cells were lysed with a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 10 mM EDTA, 0.02% NaN3, and a protease inhibitor mixture (Boehringer Mannheim, Mannheim, Germany). After being freeze-thawed once, cell lysates were centrifuged at 12,000 rpm for 20 min at 4°C. The supernatants were collected and boiled in sample buffer for 5 min. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA), blocked overnight at 4°C in PBS-T (PBS plus 0.1% Tween 20) containing 5% skim milk, and probed with Abs against caspase-3, Bcl-2, Bcl-xL, Bax, p53, cytochrome c, and {beta}-actin at 4°C overnight. After being washed with PBS-T, blots were incubated with a 1/5000 dilution of HRP-conjugated goat anti-mouse or anti-rabbit IgG for 1 h at 4°C. The protein bands were developed with an AEC substrate kit.

Flow cytometric analysis for NOS expression

A monolayer of HMEC-1 cells was cultured on sterile glass slides followed by treatment with mouse anti-NS1 or control IgG. Cells were detached using 1000 U/ml trypsin and 0.5 mM EDTA. Cells were then washed in PBS, fixed with 1% paraformaldehyde in PBS at room temperature for 10 min, and permeabilized with 70% ethanol. Rabbit anti-iNOS or anti-eNOS Abs were added to cells (5 x 105) and incubated for 1 h at 4°C. After being washed three times with PBS, cells were incubated with FITC-conjugated goat anti-rabbit IgG for 1 h at 4°C and analyzed by flow cytometry.

Determination of NO concentration

HMEC-1 culture medium was replaced by DMEM without phenol red (Sigma-Aldrich) before the cells were incubated with mouse anti-NS1 or control IgG. After various time intervals, the culture supernatant was collected, and NO production was measured by the Griess diazotization reaction to spectrophotometrically detect nitrite formed by the spontaneous oxidation of NO under physiological conditions. The Griess reagent kit for nitrite determination (Molecular Probes, Eugene, OR) was used according to the manufacturer’s instructions. Briefly, culture supernatant was mixed with an equal volume of Griess reagent, incubated at room temperature for 10 min, and then spectrophotometrically quantified by an Emax microplate reader at 548 nm (Molecular Devices, Sunnyvale, CA). NaNO2 was used as a standard, and the standard curve of nitrite concentration against its OD was plotted.

Annexin V staining

A modified staining assay of apoptotic cells with annexin V was performed according to the method of Vermes et al. (36). HMEC-1 cells (106 per test) were collected from the glass slide after incubation with mouse anti-NS1 or control IgG for various time intervals, washed twice with PBS, and resuspended in annexin V binding buffer (10 mM HEPES-NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2). After centrifugation, cells were incubated in 100 µl of the same buffer containing 5 µl FITC-conjugated annexin V (BD PharMingen) at room temperature for 15 min in the dark and then analyzed by flow cytometry.

RT-PCR

Total cellular RNA was extracted by an Ultraspec-II RNA isolation system (Biotecx, Houston, TX) following the manufacturer’s instructions. The concentration of RNA was quantified by spectrophotometry at 260 nm (U-2000; Hitachi, Tokyo, Japan). The cDNA in a total volume of 100 µl was prepared after reverse transcription of cellular RNA (20 µg) with Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) using an 18-mer of oligo(dT) as the primer. The cDNA (3 µl) was added to the PCR buffer containing primers at 1.5 µM each, MgCl2 (1.5 mM), dNTPs (0.2 mM each), and 1 U of Taq DNA polymerase (Promega) in a total reaction volume of 50 µl. The oligonucleotide primers for human Bcl-2 (5'-ACAACATCGCCCTGTGGATGA-3' and 5'-ATAGCTGATTCGACGTTTTGCC-3'), Bcl-xL (5'-TGGTCGACTTTCTCTCCTAC-3' and 5'-AGAGTTCCACAAAAGTATCC-3'), Bax (5'-GGAATTCTGACGGCAACTTCAACTGGG-3' and 5'-GGAATTCTTCCAGATGGTGAGCGAGG-3'), p53 (5'-GACAGCCAAGTCTGTGACTT-3' and 5'-CAGCATCTTATCCGAGTGGAA-3'), and {beta}-actin (5'-AGCGGGAAATCGTGCGTG-3' and 5'-CAGGGTACATGGTGGTGGTGCC-3') were used according to previously published sequences (37, 38). Thirty-five cycles were used for Bcl-2, Bcl-xL, Bax, and p53, and 30 cycles for {beta}-actin (95°C for 1 min, 55°C for 2 min, and 72°C for 3 min) using a PCR controller (GeneAmp PCR System 2400; PerkinElmer, Wellesley, MA). The PCR products were separated by 1.5% agarose gel electrophoresis, stained with ethidium bromide, and viewed with UV light.

Statistical analysis

Between-group comparisons were performed using Student’s t test with SigmaPlot version 4.0 for Windows (Cytel Software, Cambridge, MA). Values of p < 0.05 were considered significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Anti-NS1 Abs generated in mice cross-react with human endothelial cells and induce apoptosis

In the present study, we showed that anti-dengue NS1 could cross-react with endothelial cells. The binding activity of anti-NS1 IgG from hyperimmunized mouse sera with HMEC-1 cells was viewed with confocal microscopy (Fig. 1GoA); a subsequent flow cytometric analysis showed the percentages of fluorescence-positive cells (Fig. 1GoB). Unlike anti-dengue NS1 IgG, the anti-JEV NS1 IgG did not show the cross-reaction with HMEC-1 cells exerting a level similar to that of the control IgG. Anti-dengue NS1 binding activity could also be observed in HUVEC (data not shown) and in the vascular endothelium of a mouse vessel ex vivo (Fig. 2Go). Staining with CD31 marker was used as the positive control for vessel endothelium, whereas anti-JEV NS1 showed a negative result similar to that of the control IgG.



View larger version (35K):
[in this window]
[in a new window]
 
FIGURE 1. Mouse anti-DV NS1 Abs cross-react with human endothelial cells. HMEC-1 cells were incubated with 5 µg of mouse anti-NS1 IgG or control IgG, followed by FITC-conjugated anti-mouse IgG and viewed with confocal microscopy (A). The binding ability was further analyzed by flow cytometry. B, A set of representative data and the percentages of HMEC-1 cells reactive with anti-DV2 NS1 IgG, anti-JEV NS1 IgG, or control IgG. 2°, Secondary.

 


View larger version (129K):
[in this window]
[in a new window]
 
FIGURE 2. Binding ability of anti-DV NS1 Abs with mouse vessel endothelium. Mouse vessels from small veins of BALB/c mice were perfused with anti-CD31, anti-DV2 NS1, anti-JEV NS1, or control IgG. The vessel sections were prepared, incubated with HRP-conjugated goat anti-mouse IgG, and developed with the AEC substrate kit.

 
Apoptotic HMEC-1 cell death induced by anti-NS1 IgG was demonstrated by TUNEL assay followed by flow cytometric analysis (Fig. 3GoA). Apoptosis could be detected at 12 h; it increased at 24 h. Treatment with caspase inhibitor zVAD-fmk inhibited cell death. Similar results were obtained when fragmented DNA was detected on gel (Fig. 3GoB).



View larger version (67K):
[in this window]
[in a new window]
 
FIGURE 3. Anti-NS1 Abs induce endothelial cells to undergo apoptosis. HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for 12 or 24 h in the absence or presence of 4 µM zVAD-fmk, a broad spectrum caspase inhibitor, followed by TUNEL reaction and flow cytometric analysis. A, Percentages of apoptotic cells are shown as mean ± SD of duplicate cultures. *, p < 0.05. B, DNA from HMEC-1 cells was extracted and the fragmented DNA was detected by agarose gel electrophoresis.

 
Activation of caspase-3 during anti-NS1-induced apoptosis in HMEC-1 cells

Fig. 3Go shows that the induction of endothelial cell apoptosis by anti-NS1 was caspase dependent, so the involvement of caspase-3 in this process was further examined. Immunohistochemical staining revealed the presence of active form caspase-3-positive cells in HMEC-1 cells treated with anti-NS1 but not with control IgG (Fig. 4GoA). The increase in 17-kDa active caspase-3 fragments and the decrease in 32-kDa procaspase-3 could be detected in anti-NS1-treated HMEC-1 cells by Western blot analysis (Fig. 4GoB). The caspase-3 inhibitor DEVD-fmk inhibited the formation of 17-kDa caspase-3 cleavage products (Fig. 4GoB) and active-form positive cells (Fig. 4GoA). The percentages of active form caspase-3-positive cells were further quantified by flow cytometry and showed a positive correlation with the percentages of apoptotic cells as determined by TUNEL reaction (Fig. 4GoC). To further demonstrate whether caspase-3 activation is requisite for the endothelial cell apoptosis mediated by anti-NS1, the effect of DEVD-fmk was examined. Results showed that the inhibition of caspase-3 caused a blockage of endothelial cell apoptosis (Fig. 4GoC).



View larger version (63K):
[in this window]
[in a new window]
 
FIGURE 4. Anti-NS1 Abs induce activation of caspase-3 in endothelial cells. HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for 12 or 24 h with or without 4 µM DEVD-fmk. A, Expression of active caspase-3 was detected by immunohistochemical staining. Arrowheads, Cells containing active form caspase-3. B, Activation of caspase-3 analyzed by Western blot shows a decrease of 32-kDa proform and an increase in 17-kDa fragments of caspase-3 after anti-NS1 treatment. C, Percentages of cells with active caspase-3 were analyzed by flow cytometry using Abs specific for active form caspase-3. The percentages of cells undergoing apoptosis were determined by TUNEL reaction followed by flow cytometric analysis. The effects of DEVD-fmk on caspase-3 activation and cell apoptosis were also determined. Data are presented as mean ± SD of duplicate cultures. *, p < 0.05.

 
NOS expression and NO production after anti-NS1 treatment of HMEC-1 cells

In an attempt to investigate the signaling pathways in anti-NS1-induced apoptosis, iNOS and eNOS expression and NO production were monitored in HMEC-1 cells. Results showed that after treatment with anti-NS1 IgG, there was a prominent increase in iNOS expression as demonstrated by both the percentages of positive cells and the mean fluorescence intensity (MFI) (Fig. 5GoA, left). Although an increase in eNOS expression was also detectable, the increase in MFI was very small when compared with the group without anti-NS1 treatment and to the IgG control group (Fig. 5GoA, right). The expression of iNOS could be observed after anti-NS1 treatment for as short as 3 h and with as low as 1 µg (Fig. 5Go, B and C). Expression of iNOS was also confirmed by immunohistochemical staining; it showed a time-dependent expression of iNOS after treatment with anti-NS1 but not with control IgG (Fig. 5GoD). The production of NO showed positive time- and dose-dependent correlations with iNOS expression (Fig. 5Go, B and C). Furthermore, the addition of L-NAME to cell cultures caused an inhibition of NO production (Fig. 5GoB). Interestingly, the iNOS expression was also inhibited at 24 h (Fig. 5Go, B and D), but not at early stages (data not shown). Studies are under way to explore the possible mechanisms.



View larger version (51K):
[in this window]
[in a new window]
 
FIGURE 5. Time-kinetic and dose responses of NOS expression and NO production induced by anti-NS1 Abs in endothelial cells. A, HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for 12 or 24 h. The expression of iNOS and eNOS determined by flow cytometry shows the percentages of positive cells and the MFI compared with the background control using secondary Ab only (dotted lines). B, Time kinetics of the expression of iNOS as determined by the percentages of positive cells (mean ± SD of duplicate cultures) and NO production (mean ± SD of duplicate cultures) as quantified by Griess reagent kit. HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG in the presence or absence of 10 nM L-NAME. C, Dose responses of the expression of iNOS (mean ± SD of duplicate cultures) and NO production (mean ± SD of duplicate cultures) are shown. D, The expression of iNOS was detected by immunohistochemical staining using iNOS-specific Ab.

 
Requirement of NO production in HMEC-1 cell apoptosis

Whether the increase in NO production was related to the induction of endothelial cell apoptosis was queried. Both a change in cell morphology and an increase in the percentage of TUNEL-positive cells could be observed in endothelial cells treated with anti-NS1 for 24 h (Fig. 6GoA). Treatment with the NOS inhibitor L-NAME inhibited the change of morphology and reduced the percentage of TUNEL-positive cells, suggesting that NO was involved in HMEC-1 cell apoptosis. In the time-kinetic study, the exposure of phosphatidylserine (determined by annexin V staining) occurred as early as 3 h after anti-NS1 treatment, whereas DNA fragmentation (determined by TUNEL staining) was detectable at 12 h (Fig. 6GoB). L-NAME blocked both the exposure of phosphatidylserine and the fragmentation of DNA. Treatment with control IgG for 24 h exhibited basal levels similar to those of the nontreated group.



View larger version (57K):
[in this window]
[in a new window]
 
FIGURE 6. NOS inhibitor L-NAME blocks endothelial cell apoptosis induced by anti-NS1 Abs. A, HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for 24 h with or without 10 nM L-NAME. Both cell morphology and the percentages of apoptotic cells as measured by TUNEL reaction followed by flow cytometry are shown. Treatment with control IgG only showed basal levels (data not shown). B, HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for various time periods with or without 10 nM L-NAME. The percentages of apoptotic cells were determined by both annexin V and TUNEL staining followed by flow cytometric analysis. Data are presented as mean ± SD of duplicate cultures.

 
Effect of NO production on Bcl-2, Bcl-xL, Bax, and p53 expression and cytochrome c release in HMEC-1 cells

To understand the possible mechanisms of NO modulation in the apoptotic signaling pathway, expression of the Bcl-2 family proteins Bcl-2, Bcl-xL, and Bax was analyzed by Western blot (Fig. 7GoA). After treatment with anti-NS1 IgG in HMEC-1 cultures, the protein levels of Bcl-2 and Bcl-xL decreased, whereas that of Bax increased time dependently. The expression of p53 also increased. The release of cytochrome c from mitochondria was observed. Furthermore, L-NAME was able to inhibit the anti-NS1-mediated changes of Bcl-2, Bcl-xL, Bax, and p53 expression and cytochrome c release. These results revealed that the role of NO production in anti-NS1-induced endothelial cell apoptosis is the up-regulation of Bcl-2 and Bcl-xL and the down-regulation of p53 and Bax expression. The mRNA expression was further determined by RT-PCR, which showed the decrease in Bcl-2 and Bcl-xL and the increase in Bax and p53 mRNA amounts (Fig. 7GoB). Changes in mRNA expression were also inhibited by the presence of L-NAME. Therefore, the effects of NO on the expression of these molecules were on both mRNA and protein levels.



View larger version (44K):
[in this window]
[in a new window]
 
FIGURE 7. Anti-NS1 Abs cause increase in Bcl-2 and Bcl-xL expression, decrease in Bax and p53 expression, and cytochrome c (Cyt c) release, all regulated by the production of NO. HMEC-1 cells were treated with 5 µg of anti-NS1 or control IgG for 12 or 24 h with or without 10 nM L-NAME. The protein levels were determined by Western blot (A), and the mRNA were detected by RT-PCR (B). Both the mRNA and protein expression of {beta}-actin are used as internal controls.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The pathogenesis of hemorrhage in dengue disease is not well understood. Vascular leakage is one of the hallmarks of dengue hemorrhagic syndrome (3, 28). We propose a mechanism of molecular mimicry in which Abs directed against DV NS1 could cross-react with endothelial cells and induce these cells to undergo apoptosis. Evidence for this hypothesis has been obtained from mouse Abs against DV NS1 but not JEV NS1, as shown in the present study, and also from dengue patient sera (39). The signaling pathways of anti-NS1-induced apoptosis were further investigated and suggested the involvement of NO during this process. Production of NO further caused up-regulation of p53 and Bax and down-regulation of Bcl-2 and Bcl-xL, the pro- and anti-apoptotic factors that lead to cytochrome c release and caspase-3 activation. The modulations of p53, Bax, Bcl-2, and Bcl-xL by anti-NS1 IgG were on both mRNA and protein expression levels.

The endothelial cell-binding ability of anti-NS1 was demonstrated in HMEC-1 cells (Fig. 1Go), HUVEC (data not shown), and mouse vessel endothelium (Fig. 2Go). We have previously shown the cross-reaction of anti-NS1 Abs with platelets, which may explain the characteristic of thrombocytopenia (40). Liver damage is also one of the clinical features of DHF (29, 41). However, anti-NS1 did not cross-react with liver cell lines when both patient sera and mouse Abs were tested (unpublished data).

Activation of caspases is involved in the apoptotic pathway (42, 43). Our results indicated that anti-NS1 induced endothelial cell death via a caspase-dependent pathway. Caspase-3 is synthesized as a 32-kDa proform that is composed of two subunits of 17 kDa and 12 kDa (44). Western blot analysis demonstrated that anti-NS1 caused an increase in the expression of 17-kDa caspase-3 cleavage products and a decrease in the 32-kDa proform. The presence of active form caspase-3 was also confirmed by immunohistochemistry and flow cytometric analysis. Further study revealed that using specific inhibitor DEVD-fmk resulted in the blockage of endothelial cell apoptosis and inhibition of the formation of 17-kDa proteins. Activation of caspase-3 has also been shown to be inhibited by acetylaspartylglutamylvalylaspartic acid aldehyde (45, 46), which is consistent with the inhibition of 17-kDa protein formation by DEVD-fmk.

NO, generated from L-arginine by NOS, is an important multifunctional molecular mediator of physiologic and pathologic processes, including vasodilatation, inflammation, thrombosis, immune response, and neurotransmission. Generation of NO may result in either initiation or suppression of apoptosis (47, 48, 49). The involvement of NO in apoptosis induction has been reported in different cell systems, although the mechanisms are not fully understood. The involvement of several mechanisms in NO-mediated apoptosis has been proposed: peroxynitrite generation (50, 51); an increase in Bax levels (51, 52); increased expression of p53 (52, 53); activation of c-Jun N-terminal kinase/stress-activated protein kinase and p38 kinase (54, 55); ceramide formation (49); and up-regulation of Fas (56). The answers to many questions remain elusive, for example, why NO-mediated apoptosis can be both p53-dependent and -independent (57) and whether the decreased Bcl-2 expression plays a protective role or only represents a secondary phenomenon; both have been proposed (58). Until now, the effects of NO on apoptosis in endothelial cells have not been fully reported. Physiologically relevant concentrations of peroxynitrite have induced apoptosis in HL-60 and U-937 cells, but they appeared ineffective in inducing HUVEC apoptosis (50). A combination of NO and calcium mobilization has been shown to potentiate apoptosis in adrenal vascular endothelial cells (59). In the present study, NOS expression and NO production could be detected in HMEC-1 cells after binding with anti-NS1. Production of NO showed a positive correlation with the enhanced expression of iNOS. Expression of eNOS showed only a slight shift in fluorescence intensity. Interestingly, endothelial cell apoptosis induced by anti-NS1 was blocked by the addition of L-NAME. In other words, the ability of anti-NS1 to trigger endothelial cell apoptosis was a result of the production of NO. Furthermore, up-regulation of p53 and Bax expression as well as down-regulation of Bcl-2 and Bcl-xL were also blocked by the addition of L-NAME. The ratio of death antagonists (Bcl-2 and Bcl-xL) to agonists (Bax) determines whether a cell will undergo apoptosis (60). In the present study, the modulations of these molecules at both mRNA and protein levels promoted apoptotic pathways.

The intracellular redox state causes an inhibitory or enhancing effect of NO-mediated apoptosis (45, 47). NO and O2- that resulted in the reaction product peroxynitrite has been associated with apoptosis (48, 49, 50, 51). NO can cause apoptosis by triggering a mitochondrial permeability transition that involves the hypergeneration of reactive oxygen species (61). N-Acetylcysteine interfered with NO-mediated apoptosis (58). However, the radical NO and O2- interaction may also confer protection against apoptotic stimuli (48). Whether the reactive oxygen species are produced and involved in anti-NS1-induced NO-mediated apoptosis requires further investigation.

It has recently been reported that DV NS1 is expressed in a GPI-linked form that results in signal transduction, as evidenced by tyrosine phosphorylation of cellular proteins (62). Our preliminary results (unpublished) showed tyrosine phosphorylation after anti-NS1 stimulation in endothelial cells. The signal transduction pathways from tyrosine phosphorylation to iNOS expression leading to the changes in p53 and Bcl-2 family proteins require further delineation. Endothelial cells have been shown to become apoptotic in response to antagonists of integrin {alpha}v{beta}3 that cause p53 activation and p21WAF1/CIP1 expression (63). The surface molecules of endothelial cells, GPI-linked or not, recognized by anti-NS1 still need to be identified.

High levels of TNF-{alpha}, IL-6, and IL-8 have been observed in the sera of patients with DHF/DSS (22, 64, 65). DV-infected endothelial cells showed an increase in IL-6, IL-8, and RANTES secretion (21, 22). Whether anti-NS1 can elicit cytokine and chemokine production associated with the pathogenesis of DHF/DSS remains to be investigated.

Immune responses to infectious agents are the critical defense mechanisms in a host, yet abnormal immunity may also be involved in the pathogenesis of disease (20, 66, 67). We demonstrated in the present study that the generation of anti-DV NS1 Abs can cross-react with endothelial cells and induce cell damage. When taken together with previous findings that anti-NS1 present in dengue patient sera also cross-reacted with platelets (Ref. 40 and our unpublished data) and that transient thrombocytopenia in DV-infected mice was associated with the generation of anti-platelet Abs (68), this finding suggests that the onset of autoimmune responses in DV infection may have implications in DHF pathogenesis. NO-modulated endothelial cell apoptosis may play a role in the disruption of vessel endothelium and contribute to the pathogenesis of vascular leakage in DHF. Some questions remain: 1) whether these in vitro findings are involved in the in vivo mechanism; 2) whether a mechanism similar to the one found in DV-2 studies would occur in all DV serotypes. Studies are in progress to address this issue. Furthermore, studies are ongoing to identify the endothelial cell surface molecules that can be recognized by anti-NS1 Abs. Whether the epitopes shared between endothelial cell surface molecules and NS1 are conserved in all four dengue viruses remains to be assessed.


    Acknowledgments
 
We thank Y. H. Chen from the MicroElectro Mechanical Systems Research Center (National Cheng Kung University) for providing expert technical assistance with confocal laser microscopy. We acknowledge the editorial assistance of Bill Franke.


    Footnotes
 
1 This work was supported by Grant NSC90-2318-B006-007-M51 from the National Science Council, Taiwan, Republic of China. Back

2 Address correspondence and reprint requests to Dr. Yee-Shin Lin, Department of Microbiology and Immunology, National Cheng Kung University Medical College, 1 University Road, Tainan, Taiwan 701. E-mail address: yslin1{at}mail.ncku.edu.tw Back

3 Abbreviations used in this paper: DV, dengue virus; DF, dengue fever; DHF/DSS, dengue hemorrhagic fever and dengue shock syndrome; NS1, nonstructural protein 1; iNOS, inducible NO synthase; eNOS, endothelial NO synthase; L-NAME, N{omega}-nitro-L-arginine methyl ester; JEV, Japanese encephalitis virus; HMEC-1, human microvascular endothelial cell line-1; MFI, mean fluorescence intensity; z-VAD-fmk, benzyloxycarbonylvalylalanylaspartic acid fluoromethyl ketone; DEVD-fmk, aspartylglutamylvalylaspartic acid fluoromethyl ketone. Back

Received for publication December 19, 2001. Accepted for publication May 8, 2002.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Henchal, E. A., J. R. Putnak. 1990. The dengue viruses. Clin. Microbiol. Rev. 3:376.[Abstract/Free Full Text]
  2. Monath, T. P.. 1994. Dengue: the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91:2395.[Abstract/Free Full Text]
  3. Gubler, D. J.. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480.[Abstract/Free Full Text]
  4. Bhakdi, S., M. D. Kazatchkine. 1990. Pathogenesis of dengue: an alternative hypothesis. Southeast Asian J. Trop. Med. Public Health 21:652.[Medline]
  5. Bielefeldt-Ohmann, H.. 1997. Pathogenesis of dengue virus diseases: missing pieces in the jigsaw. Trends Microbiol. 5:409.[Medline]
  6. Halstead, S. B., C. N. Venkateshan, M. K. Gentry, L. K. Larsen. 1984. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J. Immunol. 132:1529.[Abstract]
  7. Halstead, S. B.. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476.[Abstract/Free Full Text]
  8. Littaua, R., I. Kurane, F. A. Ennis. 1990. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144:3183.[Abstract]
  9. Mady, B. J., D. V. Erbe, I. Kurane, M. W. Fanger, F. A. Ennis. 1991. Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc{gamma} receptors. J. Immunol. 147:3139.[Abstract]
  10. Morens, D. M.. 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:500.[Medline]
  11. Rico-Hesse, R., L. M. Harrison, R. A. Salas, D. Tovar, A. Nisalak, C. Ramos, J. Boshell, M. T. R. de Mesa, R. M. R. Nogueira, A. Travassos da Rosa. 1997. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230:244.[Medline]
  12. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos de Chacon, C. Ramos, R. Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73:4738.[Abstract/Free Full Text]
  13. Diamond, M. S., D. Edgil, T. G. Roberts, B. Lu, E. Harris. 2000. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J. Virol. 74:7814.[Abstract/Free Full Text]
  14. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, T. P. Endy, B. Raengsakulrach, A. L. Rothman, F. A. Ennis, A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2.[Medline]
  15. Kurane, I., B. L. Innis, A. Nisalak, C. Hoke, S. Nimmannitya, A. Meager, F. A. Ennis. 1989. Human T cell responses to dengue virus antigens: proliferative responses and interferon {gamma} production. J. Clin. Invest. 83:506.
  16. Mathew, A., I. Kurane, S. Green, D. W. Vaughn, S. Kalayanarooj, S. Suntayakorn, F. A. Ennis, A. L. Rothman. 1999. Impaired T cell proliferation in acute dengue infection. J. Immunol. 162:5609.[Abstract/Free Full Text]
  17. Gagnon, S. J., F. A. Ennis, A. L. Rothman. 1999. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones. J. Virol. 73:3623.[Abstract/Free Full Text]
  18. Green, S., D. W. Vaughn, S. Kalayanarooj, S. Nimmannitya, S. Suntayakorn, A. Nisalak, R. Lew, B. L. Innis, I. Kurane, A. L. Rothman, F. A. Ennis. 1999. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179:755.[Medline]
  19. King, C. A., J. S. Marshall, H. Alshurafa, R. Anderson. 2000. Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J. Virol. 74:7146.[Abstract/Free Full Text]
  20. Lei, H. Y., T. M. Yeh, H. S. Liu, Y. S. Lin, S. H. Chen, C. C. Liu. 2001. Immunopathogenesis of dengue virus infection. J. Biomed. Sci. 8:377.[Medline]
  21. Huang, Y. H., H. Y. Lei, H. S. Liu, Y. S. Lin, C. C. Liu, T. M. Yeh. 2000. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am. J. Trop. Med. Hyg. 63:71.[Abstract]
  22. Avirutnan, P., P. Malasit, B. Seliger, S. Bhakdi, M. Husmann. 1998. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J. Immunol. 161:6338.[Abstract/Free Full Text]
  23. Despres, P., M. Flamand, P.-E. Ceccaldi, V. Deubel. 1996. Human isolates of dengue type 1 virus induce apoptosis in mouse neuroblastoma cells. J. Virol. 70:4090.[Abstract]
  24. Marianneau, P., A. Cardona, L. Edelman, V. Deubel, P. Despres. 1997. Dengue virus replication in human hepatoma cells activates NF-{kappa}B which in turn induces apoptotic cell death. J. Virol. 71:3244.[Abstract]
  25. Despres, P., M. P. Frenkiel, P. E. Ceccaldi, C. Duarte dos Santos, V. Deubel. 1998. Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. J. Virol. 72:823.[Abstract/Free Full Text]
  26. Marianneau, P., M. Flamand, V. Deubel, P. Despres. 1998. Apoptotic cell death in response to dengue virus infection: the pathogenesis of dengue haemorrhagic fever revisited. Clin. Diagn. Virol. 10:113.[Medline]
  27. Jan, J. T., B. H. Chen, S. H. Ma, C. I. Liu, H. P. Tsai, H. C. Wu, S. Y. Jiang, K. D. Yang, M. F. Shaio. 2000. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-{kappa}B are sequentially involved. J. Virol. 74:8680.[Abstract/Free Full Text]
  28. Bhamarapravati, N.. 1989. Hemostatic defects in dengue hemorrhagic fever. Rev. Infect. Dis. 11:S826.
  29. Rothman, A. L., F. A. Ennis. 1999. Immunopathogenesis of dengue hemorrhagic fever. Virology 257:1.[Medline]
  30. Anderson, R., S. Wang, C. Osiowy, A. C. Issekutz. 1997. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J. Virol. 71:4226.[Abstract]
  31. Andrews, B. S., A. N. Theofilopoulos, C. J. Peters, D. J. Loskutoff, W. E. Brandt, F. J. Dixon. 1978. Replication of dengue and Junin viruses in cultured rabbit and human endothelial cells. Infect. Immun. 20:776.[Abstract/Free Full Text]
  32. Falconar, A. K. I.. 1997. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch. Virol. 142:897.[Medline]
  33. Lin, Y. L., L. K. Chen, C. L. Liao, C. T. Yeh, S. H. Ma, J. L. Chen, Y. L. Huang, S. S. Chen, H. Y. Chiang. 1998. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J. Virol. 72:191.[Abstract/Free Full Text]
  34. Chen, W. H., Y. L. Lin, C. L. Liao, S. L. Hsieh. 2000. Modulatory effects of the human heat shock protein 70 on DNA vaccination. J. Biomed. Sci. 7:412.[Medline]
  35. Ades, E. W., F. J. Candal, R. A. Swerlick, V. G. George, S. Summers, D. C. Bosse, T. J. Lawley. 1992. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99:683.[Medline]
  36. Vermes, I., C. Haanen, H. Steffens-Nakken, C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184:39.[Medline]
  37. Dibbert, B., I. Daigle, D. Braun, C. Schranz, M. Weber, K. Blaser, U. Zangemeister-Wittke, A. N. Akbar, H. U. Simon. 1998. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 92:778.[Abstract/Free Full Text]
  38. Boise, L. H., M. Gonzalez-Garcia, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. Nunez, C. B. Thompson. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597.[Medline]
  39. Lin, C. F., H. Y. Lei, A. L. Shiau, C. C. Liu, H. S. Liu, T. M. Yeh, S. H. Chen, and Y. S. Lin. 2002. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J. Med. Virol. In press.
  40. Lin, C. F., H. Y. Lei, C. C. Liu, H. S. Liu, T. M. Yeh, S. T. Wang, T. I. Yang, F. C. Sheu, C. F. Kuo, Y. S. Lin. 2001. Generation of IgM anti-platelet autoantibody in dengue patients. J. Med. Virol. 63:143.[Medline]
  41. Kalayanarooj, S., D. W. Vaughn, S. Nimmannitya, S. Green, S. Suntayakorn, N. Kunentrasai, W. Viramitrachai, S. Ratanachueke, S. Kiatpolpoj, B. L. Innis, et al 1997. Early clinical and laboratory indictors of acute dengue illness. J. Infect. Dis. 176:313.[Medline]
  42. Nunez, G., M. A. Benedict, Y. Hu, N. Inohara. 1998. Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237.[Medline]
  43. Grutter, M. G.. 2000. Caspases: key players in programmed cell death. Curr. Opin. Struct. Biol. 10:649.[Medline]
  44. Cohen, G. M.. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326:1.
  45. Li, J., C. A. Bombeck, S. Yang, Y. M. Kim, T. R. Billiar. 1999. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J. Biol. Chem. 274:17325.[Abstract/Free Full Text]
  46. Gamen, S., A. Anel, P. Perez-Galan, P. Lasierra, D. Johnson, A. Pineiro, J. Naval. 2000. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes {Delta}{Psi}m loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp. Cell Res. 258:223.[Medline]
  47. Nicotera, P., B. Brune, G. Bagetta. 1997. Nitric oxide: inducer or suppressor of apoptosis?. Trends Pharmacol. Sci. 18:189.[Medline]
  48. Brune, B., A. von Knethen, K. B. Sandau. 1998. Nitric oxide and its role in apoptosis. Eur. J. Pharmacol. 351:261.[Medline]
  49. Chung, H. T., H. O. Pae, B. M. Choi, T. R. Billiar, Y. M. Kim. 2001. Nitric oxide as a bioregulator of apoptosis. Biochem. Biophys. Res. Commun. 282:1075.[Medline]
  50. Lin, K. T., J. Y. Xue, M. Nomen, B. Spur, P. Y.-K. Wong. 1995. Peroxynitrite-induced apoptosis in HL-60 cells. J. Biol. Chem. 270:16487.[Abstract/Free Full Text]
  51. Arstall, M. A., D. B. Sawyer, R. Fukazawa, R. A. Kelly. 1999. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ. Res. 85:829.[Abstract/Free Full Text]
  52. Me{beta}mer, U. K., J. C. Reed, B. Brune. 1996. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J. Biol. Chem. 271:20192.[Abstract/Free Full Text]
  53. Iwashina, M., M. Shichiri, F. Marumo, Y. Hirata. 1998. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 98:1212.[Abstract/Free Full Text]
  54. So, H. S., R. K. Park, M. S. Kim, S. R. Lee, B. H. Jung, S. Y. Chung, C. D. Jun, H. T. Chung. 1998. Nitric oxide inhibits c-Jun N-terminal kinase 2 (JNK2) via S-nitrosylation. Biochem. Biophys. Res. Commun. 247:809.[Medline]
  55. Jun, C. D., C. D. Oh, H. J. Kwak, H. O. Pae, J. C. Yoo, B. M. Choi, J. S. Chun, R. K. Park, H. T. Chung. 1999. Overexpression of protein kinase C isoforms protects RAW 264.7 macrophages from nitric oxide-induced apoptosis: involvement of c-Jun N-terminal kinase/stress-activated protein kinase, p38 kinase, and CPP-32 protease pathways. J. Immunol. 162:3395.[Abstract/Free Full Text]
  56. Fukuo, K., S. Hata, T. Suhara, T. Nakahashi, Y. Shinto, Y. Tsujimoto, S. Morimoto, T. Ogihara. 1996. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 27:823.[Abstract/Free Full Text]
  57. Messmer, U. K., B. Brune. 1995. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem. J. 319:299.
  58. Brockhaus, F., B. Brune. 1998. U937 apoptotic cell death by nitric oxide: Bcl-2 downregulation and caspase activation. Exp. Cell Res. 238:33.[Medline]
  59. Lopez-Collazo, E., J. Mateo, M. T. Miras-Portugal, L. Bosca. 1997. Requirement of nitric oxide and calcium mobilization for the induction of apoptosis in adrenal vascular endothelial cells. FEBS Lett. 413:124.[Medline]
  60. Kroemer, G.. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis: the mechanism of action of Bcl-2 provides clues for therapeutic interventions. Nat. Med. 3:614.[Medline]
  61. Hortelano, S., B. Dallaporta, N. Zamzami, T. Hirsch, S. A. Susin, I. Marzo, L. Bosca, G. Kroemer. 1997. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett. 410:373.[Medline]
  62. Jacobs, M. G., P. J. Robinson, C. Bletchly, J. M. Mackenzie, P. R. Young. 2000. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB J. 14:1603.[Abstract/Free Full Text]
  63. Stromblad, S., J. C. Becker, M. Yebra, P. C. Brooks, D. A. Cheresh. 1996. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin {alpha}v{beta}3 during angiogenesis. J. Clin. Invest. 98:426.[Medline]
  64. Hober, D., L. Poli, B. Roblin, P. Gestas, E. Chungue, G. Granic, P. Imbert, J. Pecarere, R. Vergez-Pascal, P. Wattre, M. Maniez-Montreuil. 1993. Serum levels of tumor necrosis factor-{alpha} (TNF-{alpha}), interleukin-6 (IL-6), and interleukin-1{beta} (IL-1{beta}) in dengue-infected patients. Am. J. Trop. Med. Hyg. 48:324.
  65. Raghupathy, R., U. C. Chaturvedi, H. Al-Sayer, E. A. Elbishbishi, R. Agarwal, R. Nagar, S. Kapoor, A. Misra, A. Mathur, H. Nusrat, et al 1998. Elevated levels of IL-8 in dengue hemorrhagic fever. J. Med. Virol. 56:280.[Medline]
  66. Rose, N. R.. 1998. The role of infection in the pathogenesis of autoimmune disease. Semin. Immunol. 10:5.[Medline]
  67. Kaplan, C., F. Morinet, J. Cartron. 1992. Virus-induced autoimmune thrombocytopenia and neutropenia. Semin. Hematol. 29:34.[Medline]
  68. Huang, K. J., S. Y. J. Li, S. C. Chen, H. S. Liu, Y. S. Lin, T. M. Yeh, C. C. Liu, H. Y. Lei. 2000. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J. Gen. Virol. 81:2177.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
B. E. E. Martina, P. Koraka, and A. D. M. E. Osterhaus
Dengue Virus Pathogenesis: an Integrated View
Clin. Microbiol. Rev., October 1, 2009; 22(4): 564 - 581.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M.-C. Chen, C.-F. Lin, H.-Y. Lei, S.-C. Lin, H.-S. Liu, T.-M. Yeh, R. Anderson, and Y.-S. Lin
Deletion of the C-Terminal Region of Dengue Virus Nonstructural Protein 1 (NS1) Abolishes Anti-NS1-Mediated Platelet Dysfunction and Bleeding Tendency
J. Immunol., August 1, 2009; 183(3): 1797 - 1803.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
V. D. Krishna, M. Rangappa, and V. Satchidanandam
Virus-Specific Cytolytic Antibodies to Nonstructural Protein 1 of Japanese Encephalitis Virus Effect Reduction of Virus Output from Infected Cells
J. Virol., May 15, 2009; 83(10): 4766 - 4777.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
H.-J. Cheng, C.-F. Lin, H.-Y. Lei, H.-S. Liu, T.-M. Yeh, Y.-H. Luo, and Y.-S. Lin
Proteomic Analysis of Endothelial Cell Autoantigens Recognized by Anti-Dengue Virus Nonstructural Protein 1 Antibodies
Experimental Biology and Medicine, January 1, 2009; 234(1): 63 - 73.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C.-Y. Lai, W.-Y. Tsai, S.-R. Lin, C.-L. Kao, H.-P. Hu, C.-C. King, H.-C. Wu, G.-J. Chang, and W.-K. Wang
Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II
J. Virol., July 1, 2008; 82(13): 6631 - 6643.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
T. Chareonsirisuthigul, S. Kalayanarooj, and S. Ubol
Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells
J. Gen. Virol., February 1, 2007; 88(2): 365 - 375.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. M. Chung, M. K. Liszewski, G. Nybakken, A. E. Davis, R. R. Townsend, D. H. Fremont, J. P. Atkinson, and M. S. Diamond
From the Cover: West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H
PNAS, December 12, 2006; 103(50): 19111 - 19116.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K.-J. Huang, Y.-C. Yang, Y.-S. Lin, J.-H. Huang, H.-S. Liu, T.-M. Yeh, S.-H. Chen, C.-C. Liu, and H.-Y. Lei
The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection.
J. Immunol., March 1, 2006; 176(5): 2825 - 2832.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. M. Chung, G. E. Nybakken, B. S. Thompson, M. J. Engle, A. Marri, D. H. Fremont, and M. S. Diamond
Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc {gamma} Receptor-Dependent and -Independent Mechanisms
J. Virol., February 1, 2006; 80(3): 1340 - 1351.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. Alcon-LePoder, M.-T. Drouet, P. Roux, M.-P. Frenkiel, M. Arborio, A.-M. Durand-Schneider, M. Maurice, I. Le Blanc, J. Gruenberg, and M. Flamand
The Secreted Form of Dengue Virus Nonstructural Protein NS1 Is Endocytosed by Hepatocytes and Accumulates in Late Endosomes: Implications for Viral Infectivity
J. Virol., September 1, 2005; 79(17): 11403 - 11411.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
C.-F. Kuo, C.-C. Chen, Y.-H. Luo, R. Y Huang, W.-J. Chuang, C.-C. Sheu, and Y.-S. Lin
Cordyceps sinensis mycelium protects mice from group A streptococcal infection
J. Med. Microbiol., August 1, 2005; 54(8): 795 - 802.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
I.-K. LEE, J.-W. LIU, and K. D. YANG
CLINICAL CHARACTERISTICS AND RISK FACTORS FOR CONCURRENT BACTEREMIA IN ADULTS WITH DENGUE HEMORRHAGIC FEVER
Am J Trop Med Hyg, February 1, 2005; 72(2): 221 - 226.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-F. Lin, S.-C. Chiu, Y.-L. Hsiao, S.-W. Wan, H.-Y. Lei, A.-L. Shiau, H.-S. Liu, T.-M. Yeh, S.-H. Chen, C.-C. Liu, et al.
Expression of Cytokine, Chemokine, and Adhesion Molecules during Endothelial Cell Activation Induced by Antibodies against Dengue Virus Nonstructural Protein 1
J. Immunol., January 1, 2005; 174(1): 395 - 403.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
G N Malavige, S Fernando, D J Fernando, and S L Seneviratne
Dengue viral infections
Postgrad. Med. J., October 1, 2004; 80(948): 588 - 601.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Dugue, R. Perraut, P. Youinou, and Y. Renaudineau
Effects of Anti-Endothelial Cell Antibodies in Leprosy and Malaria
Infect. Immun., January 1, 2004; 72(1): 301 - 309.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
R. V. Warke, K. Xhaja, K. J. Martin, M. F. Fournier, S. K. Shaw, N. Brizuela, N. de Bosch, D. Lapointe, F. A. Ennis, A. L. Rothman, et al.
Dengue Virus Induces Novel Changes in Gene Expression of Human Umbilical Vein Endothelial Cells
J. Virol., November 1, 2003; 77(21): 11822 - 11832.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
Y.-W. Lin, K.-J. Wang, H.-Y. Lei, Y.-S. Lin, T.-M. Yeh, H.-S. Liu, C.-C. Liu, and S.-H. Chen
Virus Replication and Cytokine Production in Dengue Virus-Infected Human B Lymphocytes
J. Virol., October 25, 2002; 76(23): 12242 - 12249.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.-F.
Right arrow Articles by Lin, Y.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-F.
Right arrow Articles by Lin, Y.-S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS